-
-
-
-
-
-
-
Q1 MedTech quarterly preview: BTIG
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Raised to $380 at BTIG
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Insulet Corporation (PODD), CFO transition seed as a modest surprise
-
-
-
-
-
-
-
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency¹)
-
-
-
-
-
-
-
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
-
-
-
-
-
-
-
Use the pullback to buy pullback in this MedTech stock: JPMorgan
-
-
-
-
-
-
-
3 MedTech stocks to own - Citi
-
1,198,712 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

